Z160: Completed Phase IIa enrollment

Zalicus completed enrollment of about 140 patients with lumbosacral radiculopathy in a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 375 mg oral Z160 twice daily for 6 weeks. Zalicus also announced it completed enrollment of 140 patients with postherpetic neuralgia (PHN) in a Phase IIa trial. Data from both trials are expected late in 4Q13. ...